Oramed Pharmaceuticals (ORMP) Accumulated Expenses (2018 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Accumulated Expenses came in at $475000.0 in Q1 2026, up 166.85% YoY from $178000.0 in Q1 2025, and down 56.18% on a QoQ basis from $1.1 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) Accumulated Expenses (2018 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 9 years of Accumulated Expenses data on file, last reported at $475000.0 in Q1 2026.
- Quarterly Accumulated Expenses rose 166.85% year-over-year to $475000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $475000.0 (up 166.85% YoY) and the FY2025 annual result came in at $1.1 million, up 169.65% from the prior year.
- Accumulated Expenses fell to $475000.0 in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $1.1 million in Q4 2025 to a low of $21000.0 in Q4 2022.
- A 5-year average of $288461.5 and a median of $178000.0 in 2025 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Accumulated Expenses surged 2780.95% — and 2024, when it sank 33.55%.
- Tracing ORMP's Accumulated Expenses over 5 years: stood at $21000.0 in 2022, then surged by 2780.95% to $605000.0 in 2023, then slumped by 33.55% to $402000.0 in 2024, then surged by 169.65% to $1.1 million in 2025, then sank by 56.18% to $475000.0 in 2026.
- The last three Accumulated Expenses figures came in at $475000.0 (Q1 2026), $1.1 million (Q4 2025), and $585000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.26 Mn |
| Mar 31, 2026 | 475,000.00 |
| Dec 31, 2025 | 1.08 Mn |
| Sep 30, 2025 | 585,000.00 |
| Jun 30, 2025 | 259,000.00 |
| Mar 31, 2025 | 178,000.00 |
| Dec 31, 2024 | 402,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Mar 31, 2024 | 29,000.00 |
| Dec 31, 2023 | 605,000.00 |
| Sep 30, 2023 | 27,000.00 |
| Jun 30, 2023 | 27,000.00 |
| Dec 31, 2022 | 21,000.00 |
| Aug 31, 2021 | 1.24 Mn |
| Aug 31, 2020 | 54,000.00 |
| Aug 31, 2019 | 25,000.00 |
| Aug 31, 2018 | 80,000.00 |